This first-in-human study will be counducted to evaluate the safety, tolerability,
pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive
Locally Advanced or Metastatic Solid Tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05523947.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Name Not Available
YH32367, a novel HER2/4-1BB bispecific antibody (BsAb), simultaneously targets HER2 and
h4-1BB and binds to both targets. YH32367 exhibits a strong 4-1BB signal activation as
well as blocking of HER2 signaling in HER2-expressing tumor cells. YH32367 stimulates
IFN-γ secretion from T cells and thereby induces tumor cells lysis.
This is a Phase 1/2, open-label, multicenter, first-in-human study of YH32367. This
2-part study will include both a Dose Escalation part, to identify the Maximum Tolerated
Dose (MTD) and/or two dose levels for RP2D selection, and a Dose Expansion part, to
determine RP2D and to confirm the safety, tolerability and efficacy of YH32367 at the
RP2D.
Lead OrganizationYuhan Corporation
